A Phase 1 interventional study of Lofexidine (granules for reconstitution) and LUCEMYRA (lofexidine) tablets in Normal Healthy Volunteers, sponsored by USWM, LLC (dba US WorldMeds). Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-06-15.
Sponsored by USWM, LLC (dba US WorldMeds) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this open-label, single-dose, randomized, three-treatment, three-period, four-sequence, crossover study is to evaluate the relative bioavailability of a test formulation of lofexidine granules for reconstitution (oral) and LUCEMYRA tablets under fasted conditions and to evaluate the effect of food on the relative bioavailability of lofexidine granules for reconstitution (oral) when administered under fed compared to fasted conditions.
USWM, LLC (dba US WorldMeds) is the lead sponsor of 17 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female subjects must meet at least one of the following criterion:
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be administered lofexidine granules for reconstitution following an overnight fast of at least 10 hours.
Drug: Lofexidine (granules for reconstitution)
Participants will first be administered LUCEMYRA (lofexidine) tablets following an overnight fast of at least 10 hours
Drug: LUCEMYRA (lofexidine) tablets
Participants will first be administered lofexidine granules for reconstitution, 30 minutes following a standardized breakfast preceded by an overnight fast of at least 10 hours.
Drug: Lofexidine (granules for reconstitution)
All subjects will be administered one 0.36 mg dose of lofexidine granules for reconstitution.
All subjects will be administered one 0.36 mg dose of LUCEMYRA (lofexidine) tablets.
Mean Maximum Plasma Concentration (Cmax)
The peak exposure plasma concentrations (Cmax) of lofexidine were observed and measured.
Time frame: Mean from Day 1 through Day 3 for Periods I, II, III.
Time to Maximum Plasma Concentration (Tmax)
Time to peak plasma concentration (h) collection time at which Cmax is first observed.
Time frame: Day 1 through Day 3 for Periods I, II, III.
Area Under the Plasma Concentration-time Curve From Time Zero to the Time of Last Measurable Concentration (AUC0-t)
Areas under the plasma concentration-time curve from time zero to the time of last measurable concentration (AUC0-t)
Time frame: Day 1 through Day 3 for Periods I, II, III.
Area Under the Plasma Concentration-time Curve From Time Zero to Time Infinity (AUC0-∞)
Time frame: Mean from Day 1 through Day 3 for Periods I, II, III.
First-order Terminal Rate Constant (λz)
Time frame: Mean from Day 1 through Day 3 for Periods I, II, III.
First-order Terminal Half-life (T½)
Time frame: Mean from Day 1 through Day 3 for Periods I, II, III.
Occurrence of Adverse Events (AEs)
Number of Subjects dosed for each Treatment groups: Treatment A = 15 subjects dosed; Treatment B = 16 subjects dosed; Treatment C = 15 subjects dosed
Time frame: Total from occurrences assessed daily after each dosing for Periods 1-3, as well as end of study (22 days)
| Milestone | Sequence 1: Treatment B, Treatment A, Treatment C | Sequence 2: Treatment B, Treatment C, Treatment A | Sequence 3: Treatment A, Treatment C, Treatment B | Sequence 4: Treatment C, Treatment A, Treatment B |
|---|---|---|---|---|
| Started | 4 | 4 | 4 | 4 |
| Period 1 | 4 | 4 | 4 | 4 |
| Period 2 | 3 | 4 | 4 | 4 |
| Period 3 | 3 | 4 | 4 | 4 |
| Completed | 3 | 4 | 4 | 4 |
| Not completed | 1 | 0 | 0 | 0 |
The peak exposure plasma concentrations (Cmax) of lofexidine were observed and measured.
| ng/mL | Treatment A: Lofexidine Granules - Fasted Conditions | Treatment B: LUCEMYRA Tablets - Fasted Conditions | Treatment C: Lofexidine Granules - Fed Conditions |
|---|---|---|---|
| Mean Maximum Plasma Concentration (Cmax) | 0.6984 ± 0.1661 | 0.7275 ± 0.1657 | 0.6977 ± 0.1656 |
Time to peak plasma concentration (h) collection time at which Cmax is first observed.
| hours | Treatment A: Lofexidine Granules - Fasted Conditions | Treatment B: LUCEMYRA Tablets - Fasted Conditions | Treatment C: Lofexidine Granules - Fed Conditions |
|---|---|---|---|
| Time to Maximum Plasma Concentration (Tmax) | 4.2678 ± 1.3894 | 4.3367 ± 1.2364 | 4.5344 ± 1.6435 |
Areas under the plasma concentration-time curve from time zero to the time of last measurable concentration (AUC0-t)
| h*ng/mL | Treatment A: Lofexidine Granules - Fasted Conditions | Treatment B: LUCEMYRA Tablets - Fasted Conditions | Treatment C: Lofexidine Granules - Fed Conditions |
|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero to the Time of Last Measurable Concentration (AUC0-t) | 12.1333 ± 4.965 | 12.2450 ± 4.142 | 12.4540 ± 4.517 |
| h·ng/mL | Treatment A: Lofexidine Granules - Fasted Conditions | Treatment B: LUCEMYRA Tablets - Fasted Conditions | Treatment C: Lofexidine Granules - Fed Conditions |
|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero to Time Infinity (AUC0-∞) | 14.9643 ± 6.063 | 14.7229 ± 4.411 | 14.9004 ± 5.021 |
| h^-1 | Treatment A: Lofexidine Granules - Fasted Conditions | Treatment B: LUCEMYRA Tablets - Fasted Conditions | Treatment C: Lofexidine Granules - Fed Conditions |
|---|---|---|---|
| First-order Terminal Rate Constant (λz) | 0.0549 ± 0.0150 | 0.0524 ± 0.0071 | 0.0524 ± 0.0075 |
| hours | Treatment A: Lofexidine Granules - Fasted Conditions | Treatment B: LUCEMYRA Tablets - Fasted Conditions | Treatment C: Lofexidine Granules - Fed Conditions |
|---|---|---|---|
| First-order Terminal Half-life (T½) | 13.5577 ± 3.901 | 13.4681 ± 1.881 | 13.5008 ± 2.068 |
Number of Subjects dosed for each Treatment groups: Treatment A = 15 subjects dosed; Treatment B = 16 subjects dosed; Treatment C = 15 subjects dosed
| adverse events | Treatment A: Lofexidine Granules - Fasted Conditions | Treatment B: LUCEMYRA Tablets - Fasted Conditions | Treatment C: Lofexidine Granules - Fed Conditions |
|---|---|---|---|
| Occurrence of Adverse Events (AEs) | 3 | 13 | 14 |
Collected over Daily after each dosing for Periods 1-3, as well as End of Study Day 3 Period 3 (22 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment A: Lofexidine Granules - Fasted Conditions | 0/15 (0%) | 0/15 (0%) | 3/15 (20%) |
| Treatment B: LUCEMYRA Tablets - Fasted Conditions | 0/16 (0%) | 0/16 (0%) | 8/16 (50%) |
| Treatment C: Lofexidine Granules - Fed Conditions | 0/15 (0%) | 0/15 (0%) | 7/15 (46.7%) |
| Event | Treatment A: Lofexidine Granules - Fasted Conditions | Treatment B: LUCEMYRA Tablets - Fasted Conditions | Treatment C: Lofexidine Granules - Fed Conditions |
|---|---|---|---|
| Blood pressure decreasedInvestigations | 2/15 | 4/16 | 4/15 |
| SomnolenceNervous system disorders | 1/15 | 4/16 | 3/15 |
| Decreased appetiteMetabolism and nutrition disorders | 0/15 | 0/16 | 2/15 |
| Alanine aminotransferase increasedInvestigations | 0/15 | 0/16 | 1/15 |
| NauseaGastrointestinal disorders | 0/15 | 1/16 | 1/15 |
| Abdominal painGastrointestinal disorders | 0/15 | 0/16 | 1/15 |
| Abdominal pain upperGastrointestinal disorders | 0/15 | 0/16 | 1/15 |
| PainGeneral disorders | 0/15 | 0/16 | 1/15 |
| DizzinessNervous system disorders | 0/15 | 1/16 | 0/15 |
| HeadacheNervous system disorders | 0/15 | 1/16 | 0/15 |
This is a crossover study with an enrollment of sixteen (16) healthy adult subjects. Each subject was eligible to participate in all 3 treatment group (Treatment A, Treatment B, Treatment C).
| Age, Categorical(Participants) | All Study Participants |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 16 |
| >=65 years | 0 |
| Age, Continuous(years) | All Study Participants |
|---|---|
| Mean | 35.1 ± 7.9 |
| Sex: Female, Male(Participants) | All Study Participants |
|---|---|
| Female | 3 |
| Male | 13 |
| Race (NIH/OMB)(Participants) | All Study Participants |
|---|---|
| American Indian or Alaska Native | 3 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 9 |
| White | 4 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Body Mass Index (BMI)(kg/m^2) | All Study Participants |
|---|---|
| Mean | 28.5 ± 3.2 |
| Height(cm) | All Study Participants |
|---|---|
| Mean | 175.1 ± 8.4 |
| Weight(kg) | All Study Participants |
|---|---|
| Mean | 88.0 ± 14.6 |
| Tobacco Users(Count of participants) | All Study Participants |
|---|---|
| Yes | 0 |
| No | 16 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2021 to primary completion in Mar 2021, 1 month.
Results were first posted in Jun 2022, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lofexidine
USWM, LLC (dba US WorldMeds)